PharmTech Europe News

Cannuba has announced that it is collaborating with an independent scientific body on drugs from the UK on the launch of a medical cannabis working group.

CDMO, Vibalogics, has revealed that it will be acquired by a private equity firm, Ampersand Capital Partners.

ABPI has issued a response to the recent publication of the UK's Migration Advisory Committee’s full review on the shortage occupation list.

Cegedim, has announced that it is collaborating with Sanofi to deliver real-world data for the improvement of health within Europe.

Medherant has announced that it is the recipient of a new £2-million (US$2.5-million) investment from Mercia Technologies.

The agency updated its list of recommended influenza virus strains that manufacturers should include in vaccines for the autumn 2019 season.

The agency is reviewing Xeljanz (tofacitinib) because of the risk of blood clots in the lungs.

WHP has been awarded with the design contract for the United Kingdom’s first dedicated vaccines manufacturing innovation center (VMIC).

A “Darwinian” drug discovery program aimed at tackling cancer’s ability to develop drug resistance will launch in a new center based in London, United Kingdom.

A CPhI Middle East & Africa (MEA) expert has forecasted a boom in manufacturing in the region and has expectations that within five years some of the industry will be acting as contract manufacturers for the European market.

The Association of the British Pharmaceutical Industry has issued a response to the recently aired BBC Radio 4 investigation program on opioids.

Locate Bio has been granted additional investment to the tune of £2 million (US$2.6 million) for the expansion of its cell and gene therapy pipeline.

The European Medicines Agency has issued a vacancy notice for the position of executive director.

The partnership will focus on the commercialization of inducible promoters to improve biomanufacturing.

The UK government announced during the ABPI’s recent conference that it is making improvements to the Accelerated Access Collaborative.

A UK-based company, Atelerix, has revealed that it has closed a second round of funding worth £700,000 (US$911,000).

Shakespeare Martineau, a law firm, announced that advisers from the firm have assisted Bermele with a capital-raising move worth £1 million (US $1.3 million).

It has been confirmed that both Bulgaria and Cyprus will now be able to perform GMP inspections at a level considered equivalent to the United States

Vibalogics has increased its single-use bioreactor and purification capacity with a new manufacturing for its specialist oncolytic virus and viral vector manufacturing services as a result of a growth in demand.

EMA has launched a social media campaign aimed at highlighting how the agency and its network maintain safety and efficacy of medicines available in Europe.

Catalent has revealed that it is the recipient of a silver award from the Royal Society for the Prevention of Accidents (RoSPA) in recognition of its health and safety practices.

In collaboration with Pall Corportion, biotech company Freeline completed the first full-scale run at its newly commissioned, GMP gene-therapy manufacturing facility in the UK.

NHS England and three pharma companies have agreed to work together to find and cure tens of thousands more people with hepatitis C, potentially leading to Britain becoming the first country to eliminate the virus.

The companies will join forces to use artificial intelligence (AI) and machine learning to discover and develop new treatments for two chronic diseases.

The UK’s General Pharmaceutical Council (GPhC) has strengthened its guidance for online pharmacies to further safeguard patients when purchasing medicines.

The agency recommended marketing authorization for two orphan drugs and treatments for opioid dependence, HIV, cancer, and more.

The CHMP has recommended that Sixmo (buprenorphine) be granted a marketing authorization in the EU as a substitution treatment for opioid dependence.

EMA has revealed that it is updating the prescribing information of Tyverb (lapatinib) as a result of the detection of errors in study results.

Intertek has announced the expansion of its pharmaceutical services laboratory in Melbourn, near Cambridge, UK, through the acquisition of a new 20,000 sq. ft facility.

The company’s center of excellence for advanced analytical testing passed GMP inspection from the European Medicines Agency.